Vytrus Biotech SA

Vytrus Biotech maintains a strong liquidity position, with a current ratio of 3.03 and cash and equivalents of EUR 1.5 million, indicating the company can easily cover its short-term obligations. The company's liquidity risk is assessed as low, supported by its robust cash flow generation, with operating cash flow of EUR 3.9 million and free cash flow of EUR 1.19 million. Profitability metrics show Vytrus Biotech is performing well above industry norms. The company's return on equity (ROE) of 28.1% and return on assets (ROA) of 19.75% are strong indicators of efficient capital use and asset management. The gross profit margin of 80.7% and operating margin of 38.0% further support the company's ability to maintain profitability in a competitive market. Vytrus Biotech operates as a single-segment entity, with all revenue derived from its industrial services in environmental solutions. The company's geographic exposure is not disclosed in the available data, but its revenue concentration in a single business line suggests a focused operational strategy. The company's growth trajectory is supported by its strong cash flow and profitability. While no specific revenue growth rates are provided, the company's operating cash flow and free cash flow suggest a stable and growing business. The capital expenditure of EUR -2.68 million indicates ongoing investment in infrastructure and operations. Risk factors for Vytrus Biotech are minimal, with low liquidity and dilution risks identified. The company's debt-to-equity ratio of 0.12 suggests a conservative capital structure, and no immediate filing-based liquidity or dilution flags were detected. The company's dilution potential is also low, with no recent issuance or ATM/shelf disclosures indicating near-term pressure. Recent events and filings for Vytrus Biotech do not show any material changes or risks. The company's financials remain stable, with no significant deviations in operating performance or capital structure.